Evidence map›Paper›PMID 38606776›Full record

ArticleJournal of the American Heart Association2024

Cost-Effectiveness of a Multicomponent Primary Care Intervention for Hypertension.

Junxing Chay, Tazeen H Jafar, Rebecca J Su, Rupesh M Shirore, Ngiap Chuan Tan, Eric A Finkelstein

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02972619 (Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health - A Cluster Randomized Trial in Singapore Polyclinics), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02972619 naunknown statusnot on this map

Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health - A Cluster Randomized Trial in Singapore Polyclinics

TypeinterventionalSponsorDuke-NUS Graduate Medical SchoolRan2017 to 2020Enrolled1,000ConditionsHypertension, Cardiovascular DiseaseArmsStructured Multicomponent Intervention (MCI)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Junxing ChayProgram in Health Services & Systems Research Duke-NUS Medical School Singapore.ORCID 0000-0002-3291-4523
Tazeen H JafarProgram in Health Services & Systems Research Duke-NUS Medical School Singapore.ORCID 0000-0001-7454-8376
Rebecca J SuProgram in Health Services & Systems Research Duke-NUS Medical School Singapore.ORCID 0000-0002-1804-4277
Rupesh M ShiroreProgram in Health Services & Systems Research Duke-NUS Medical School Singapore.ORCID 0000-0001-5436-4430
Ngiap Chuan TanSingHealth Polyclinics Singapore.ORCID 0000-0002-5946-1149
Eric A FinkelsteinProgram in Health Services & Systems Research Duke-NUS Medical School Singapore.ORCID 0000-0001-6443-9686
Duke-NUS Medical School · SGDuke Institute for Health Innovation · USSingapore General Hospital · SGSingHealth Polyclinics · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SingHypertension primary care clinic intervention, which consisted of clinician training in hypertension management, subsidized single-pill combination medications, nurse-delivered motivational conversations and telephone follow-ups, improved blood pressure control and cardiovascular disease (CVD) risk scores relative to usual care among patients with uncontrolled hypertension in Singapore. This study quantified the incremental cost-effectiveness, in terms of incremental cost per unit reduction disability-adjusted life years, of SingHypertension relative to usual care for patients with hypertension from the health system perspective. METHODS AND

resultsWe developed a Markov model to simulate CVD events and associated outcomes for a hypothetical cohort of patients over a 10-year period. Costs were measured in US dollars, and effectiveness was measured in disability-adjusted life years averted. We present base-case results and conducted deterministic and probabilistic sensitivity analyses. Based on a willingness-to-pay threshold of US $55 500 per DALY averted, SingHypertension was cost-effective for patients with hypertension (incremental cost-effectiveness ratio: US $24 765 per disability-adjusted life year averted) relative to usual care. This result held even if risk reduction was assumed to decline linearly to 0 over 10 years but not sooner than 7 years. Incremental cost-effectiveness ratios were most sensitive to the magnitude of the reduction in CVD risk; at least a 0.13% to 0.16% point reduction in 10-year CVD risk is required for cost-effectiveness. Probabilistic sensitivity analysis indicates that SingHypertension has a 78% chance of being cost-effective at the willingness-to-pay threshold.

conclusionsSingHypertension represents good value for the money for reducing CVD incidence, morbidity, and mortality and should be considered for wide-scale implementation in Singapore and possibly other countries. REGISTRATION INFORMATION: REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02972619.

Indexed as

HypertensionBlood PressureCost-Benefit AnalysisHumansPrimary Health CareQuality-Adjusted Life YearsSingaporeblood pressurecardiovascular riskcost‐effectivenesshypertensionmulticomponent intervention

Identifiers

PMID38606776
PMCPMC11262484
OpenAlexW4394765889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.